Adolescent thalamic inhibition leads to long-lasting impairments in prefrontal cortex function

Laura J. Benoit, Emma S. Holt, Lorenzo Posani, Stefano Fusi, Alexander Z. Harris, Sarah Canetta and Christoph Kellendonk.

Impaired cortical maturation is a postulated mechanism in the etiology of neurodevelopmental disorders, including schizophrenia. In the sensory cortex, activity relayed by the thalamus during a postnatal sensitive period is essential for proper cortical maturation. Whether thalamic activity also shapes prefrontal cortical maturation is unknown. We show that inhibiting the mediodorsal and midline thalamus in mice during adolescence leads to a long-lasting decrease in thalamo-prefrontal projection density and reduced excitatory drive to prefrontal neurons. It also caused prefrontal-dependent cognitive deficits during adulthood associated with disrupted prefrontal cross-correlations and task outcome encoding. Thalamic inhibition during adulthood had no long-lasting consequences. Exciting the thalamus in adulthood during a cognitive task rescued prefrontal cross-correlations, task outcome encoding and cognitive deficits. These data point to adolescence as a sensitive window of thalamocortical circuit maturation. Furthermore, by supporting prefrontal network activity, boosting thalamic activity provides a potential therapeutic strategy for rescuing cognitive deficits in neurodevelopmental disorders.
Fig. 1 | Adolescent, but not adult, thalamic inhibition leads to persistent cognitive impairments in adulthood. a. Adolescent experimental timeline. CNO was administered from P20 to P50 to mice expressing hM4D or GFP in the thalamus, and behavioral testing was conducted 40 d later at P90; created with https://biorender.com. b,c, Schematics of the NMS task (b) and the ASST (c). d, Adolescent inhibited hM4D animals take significantly longer to acquire the NMS task (left) and take significantly more days to reach criterion (right); control, n = 17 animals; hM4D, n = 21 animals; learning curve, two-way repeated measures analysis of variance (rmANOVA), effect of time $F_{4,200.512} = 102.0$ and $P < 0.0001$, effect of group $F_{1,49} = 3.143$ and $P = 0.0847$, effect of group $x$ time $F_{1,447} = 2.608$ and $*P = 0.0137$; days to criterion (3 consecutive days above 70%); control, 5.35 ± 0.76 d; hM4D, 7.40 ± 1.02 d; two-sided unpaired t-test: $t = 2.746$, d.f. = 36, $**P = 0.0094$. e, Adolescent inhibited hM4D animals are no different than controls in the IA of the ASST (left; control, n = 14 animals and 15.71 ± 1.88 trials; hM4D, n = 16 animals and 11.81 ± 1.50 trials; two-sided unpaired t-test, $t = 1.639$, d.f. = 28, $P = 0.125$) but take significantly more trials in the eDSS than controls (right; control, n = 14 animals and 10.57 ± 0.42 trials; hM4D, n = 15 animals and 15.07 ± 1.79 trials; unpaired t-test, $t = 2.372$, d.f. = 27, $*P = 0.0253$). f, Adult experimental timeline with CNO administered between P90 and P120 and testing at P160. g,h, There were no differences in either the acquisition of the NMS task (g; control, n = 6 animals; hM4D, n = 10 animals; learning curve: two-way rmANOVA, effect of time $F_{4,520.776} = 40.21$ and $P < 0.0001$; effect of group $F_{1,24} = 1.462$ and $P = 0.2467$; effect of group $x$ time $F_{1,240} = 0.8680$ and $P = 0.6126$; days to criterion: control, 7.33 ± 0.67 d; hM4D, 7.40 ± 1.02 d; two-sided unpaired t-test, $t = 0.04654$, d.f. = 14, $P = 0.9635$) or the IA (h; control, n = 20 animals and 10.60 ± 0.59 trials; hM4D, n = 18 animals and 11.39 ± 0.76 trials; two-sided unpaired t-test, $t = 0.8260$, d.f. = 36, $P = 0.4142$) and EDSS (control, 12.40 ± 0.89 trials; hM4D, 10.76 ± 0.64 trials; unpaired t-test, $t = 1.442$, d.f. = 35, $P = 0.1583$) portions of the ASST between adult inhibited hM4D animals and controls. Learning curves depict mean performance ± s.e.m. for each day. For other plots, dots represent individual animals; lines represent mean ± s.e.m.; $*P < 0.05$, $**P < 0.01$. 

NATURE NEUROSCIENCE | VOL 25 | JUNE 2022 | 714-725 | www.nature.com/natureneuroscience
therapeutic insights into how to reverse cognitive deficits arising from a developmentally altered brain.

**Results**

**Thalamic inhibition during adolescence or adulthood.** To inhibit thalamic activity during adolescence and adulthood, we injected an adeno-associated virus (AAV) carrying a Cre-dependent version of the inhibitory designer receptor hM4D into the thalamus of Gbx2\(^{Cre^{ERT2}}\) mice. Viral injections were performed at postnatal day 13 (P13), and Cre-mediated recombination was induced by tamoxifen injection at P15–P16 at a time when Gbx2 expression is restricted to the mediodorsal (MD) and midline thalamus, thereby limiting viral spread (Extended Data Fig. 1). To determine the efficacy of hM4D-mediated inhibition, we performed whole-cell patch clamp recordings from thalamic neurons in both adolescent and adult brain slices. Application of the designer receptors exclusively activated by designer drugs (DREADDs) ligand clozapine N-oxide (CNO) hyperpolarized thalamic neurons, consistent with activation of G-protein-coupled inward rectifying potassium channels (Extended Data Fig. 1d). Thalamic neurons in control animals did not respond to CNO. CNO application led to comparable effect sizes in adolescent and adult brain slices that were consistent with published results in adult thalamic neurons\(^2\). Crucially, CNO application hyperpolarized thalamic neurons in animals that had been exposed to twice daily intraperitoneal (i.p.) CNO injections for 15 d (P20–P35, P90–P105) or 30 d (P20–P50), suggesting that chronic hM4D activation does not lead to receptor desensitization (Extended Data Fig. 1d). These data indicate that repeated hM4D activation inhibits thalamic neuron activity during adolescence and adulthood.

**Adolescent thalamic activity is required for adult cognition.** We then tested the long-term effects of transient thalamic inhibition during adolescence (P20–P50) or prefrontal-dependent cognitive task performance. To this end, CNO (1 mg kg\(^{-1}\)) was injected twice daily in hM4D and control green fluorescent protein (GFP) in which the extra-dimensional set-shifting (EDSS) component of and an odor- and texture-based attentional set shifting task (ASST), excluding deficits in motivation or mobility.

![Fig. 2](https://biorender.com) Adulsect, but not adult, thalamic inhibition leads to a persistent reduction in excitatory drive onto mPFC pyramidal neurons. a. Adolescent experimental timeline and schematic. Whole-cell patch clamp recordings were made from pyramidal cells in layer II/III of the mPFC from hM4D and control mice. These pyramidal cells receive excitatory inputs from the thalamus as well as inhibitory inputs from local interneurons; created with https://biorender.com. b. Representative traces showing sEPSCs (left) and sIPSCs (right). c, sEPSC frequency is significantly reduced following adolescent thalamic inhibition relative to control mice, but sIPSC amplitude is unchanged; control, n = 20 cells and 5 animals; hM4D, n = 24 cells and 7 animals; frequency: control 4.438 ± 0.429 Hz and hM4D 3.202 ± 0.325 Hz; t-test, t = -2.337, d.f. = 42, P = 0.0243; amplitude: control 28.71 ± 2.57 pA and hM4D 29.82 ± 1.47 pA; unpaired t-test, t = 0.3881, d.f. = 42, P = 0.6999. d, sIPSC frequency and amplitude are also unchanged; control, n = 20 cells and 5 animals; hM4D, n = 21 cells and 7 animals; frequency: control 3.421 ± 0.376 Hz and hM4D 2.627 ± 0.323 Hz; t-test, t = 1.606, d.f. = 39, P = 0.1163; amplitude: control 32.29 ± 2.08 pA and hM4D 31.03 ± 1.84 pA; unpaired t-test, t = 0.4450, d.f. = 34, P = 0.6592. e, Adult experimental timeline. f, g, sEPSC (f) and sIPSC (g) frequency and amplitude are unchanged following adult thalamic inhibition; control, n = 12 cells and 3 animals; hM4D, n = 12 cells and 3 animals; sEPSC, n = 12 control cells and n = 12 hM4D cells; frequency: control 4.674 ± 0.448 Hz and hM4D 4.675 ± 0.561 Hz; t-test, t = 0.001936, d.f. = 22, P = 0.9985; amplitude: control 27.78 ± 1.68 pA and hM4D 29.75 ± 1.78 pA; unpaired t-test, t = 0.8048, d.f. = 22, P = 0.4296; sIPSC, n = 12 control cells and n = 12 hM4D cells; frequency: control 3.775 ± 0.506 Hz and hM4D 2.825 ± 0.625 Hz; unpaired t-test, t = 1.181, d.f. = 22, P = 0.2501; amplitude: control 25.49 ± 0.82 pA and hM4D 23.69 ± 1.82 pA; two-sided unpaired t-test, t = 0.9030, d.f. = 22, P = 0.3763. Dots represent individual animals, and lines represent mean ± s.e.m.; *P < 0.05.

Similarly, in the ASST, we found that the mPFC-dependent EDSS was impaired in animals expressing hM4D compared to controls (Fig. 1e). Meanwhile, behavior in the non-mPFC-dependent initial acquisition (IA) portion of the set shifting task was unchanged. No changes were seen in any other task variables, including IA or EDSS task latencies (Extended Data Fig. 2f–h).

To address whether the primary contribution of this behavioral deficit came from projections to the mPFC, as opposed to other thalamic projections, we selectively inhibited thalamo–mPFC projections during adolescence. We used a dual virus approach, injecting a retrogradely transported AAV expressing Cre recombine into the mPFC and an AAV-expressing Cre-dependent hM4D into the thalamus (Extended Data Fig. 3a). Using this method, hM4D expression was restricted to thalamic cells projecting to the mPFC (Extended Data Fig. 3b,c). As in Fig. 1d, we observed intact IA and impaired EDSS after projection-specific inhibition (Extended Data Fig. 3d,e).

To determine whether adolescence is a sensitive period or whether the circuit is sensitive to transient changes at any age, we also inhibited the thalamus for a comparable time window during adulthood, P90–P120, and tested the mice 40 d later at P160 (Fig. 1f).

While there was an effect of age on performance in the NMS task with the older P160 animals performing worse than the P90 animals, adult thalamic inhibition affected neither acquisition of the NMS task (Fig. 1g) nor trials to criterion in the EDSS task (Fig. 1h), supporting the hypothesis that adolescence is a sensitive period in which changes in thalamic activity influence the development of thalamo–mPFC circuit maturation.

**Adolescent thalamic activity regulates adult mPFC excitation.** To determine whether thalamic inhibition during adolescence leads to long-lasting changes in mPFC circuit function, we used slice physiology to measure spontaneous excitatory and inhibitory activity in mPFC layer II/III pyramidal cells, which receive projections from the thalamus (Fig. 2a). Following adolescent thalamic inhibition, the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) was reduced, while the sEPSC amplitude was unchanged (Fig. 2b,c). This change in frequency, but not amplitude, suggests a decrease in presynaptic excitatory inputs. By contrast, we found no changes in frequency or amplitude of spontaneous inhibitory postsynaptic currents (sIPSCs; Fig. 2d).

These effects were again selective to thalamic inhibition during adolescence, as we found no changes in excitatory or inhibitory inputs following chronic thalamic inhibition in adulthood (Fig. 2e–g). Consistent with the behavioral results, these results point to adolescence as a sensitive time period during which thalamic activity regulates the development of the mPFC. Note that adolescent thalamic inhibition did not alter the intrinsic properties and excitatory inputs to MD thalamic neurons (Extended Data Fig. 4).
Adolescent activity regulates adult thalamo–mPFC projections. We next determined whether decreased subcortical anatomical inputs may contribute to the decrease in sEPSC frequency. To address this question, we injected a retrogradely transported fluorescent protein, GFP, into the mPFC of adult mice that had experienced adolescent thalamic inhibition. Three weeks later, we calculated the density of retrogradely labeled neurons in the thalamus and basolateral amygdala (BLA; Fig. 3a,b), which both project to layer II/III of the mPFC. We observed a decrease in the density of cells projecting from the thalamus to the mPFC in adult mice (Fig. 3c), which already emerged at P35 (Extended Data Fig. 5). By contrast, we found no change in the density of cells projecting from the BLA (Fig. 3d,e), suggesting that there is no global competition between subcortical mPFC projections, as has previously been observed after early postnatal lesion studies28. We measured no change in overall cell density within the thalamus based on DAPI-positive cell counts (two-sided unpaired t-test, t = 0.6050, d.f. = 11, P = 0.5575), suggesting a loss of thalamic inputs to the mPFC rather than thalamic cells.
Adult thalamic excitation rescues the cognitive deficit. The anatomical changes suggest the circuit alterations are persistent. Previous work has shown that exciting the thalamus enhances performance in prefrontal-dependent working memory and two-alternative forced choice tasks.

Therefore, we excited the thalamus during the set shifting task using a stabilized step function opsin (SSFO; Fig. 4a). We activated the SSFO with a 5-s pulse (473 nm, 4 mW) before the start of the EDSS portion of the task (Fig. 4b). Because the SSFO will slowly inactivate over time, we repeated the 5-s pulse every 30 min during the intertrial interval (ITI) of the task.

We performed a crossover experiment where each animal performed the ASST twice with and without SSFO activation 10 d apart. We replicated the behavioral deficit described in Fig. 1e and found that increasing thalamic excitability via SSFO activation during EDSS rescued the deficit in EDSS (Fig. 4c,d). The effects of SSFO activation did not persist from the first day of testing to the second testing day, and repeating the experiment did not influence behavior (two-way rmANOVA; effect of light F1,16 = 6.302 and P = 0.0156, effect of run day F1,46 = 2.512 and P = 0.1199, effect of light x day run F1,46 = 1.364 and P = 0.2488). Thus, even though the sensitive period of circuit maturation occurs in adolescence, activating thalamo-mPFC circuitry can still rescue the behavioral deficits in adulthood.

Oscillatory activity does not explain cognitive deficits. To better understand the network mechanisms driving behavioral deficits, we examined several metrics of mPFC activity during the behavior, such as local field potential (LFP) activity, single-unit cellular activity and neural ensemble activity.

Prior work using the same set shifting task identified an increase in the power of gamma frequency (40–90 Hz) oscillations in the mPFC before correct, but not incorrect, choices during the EDSS behavior.

Consistent with these prior results, we found that mPFC gamma power was increased in correct versus incorrect trials before the mouse made a decision (Fig. 5a,b,c). However, this difference was observed in both controls and after adolescent inhibition of the MD thalamus, albeit with a smaller-appearing effect size (Fig. 5b,d). Moreover, thalamic SSFO activation had no significant effect on mPFC gamma power (Fig. 5c–e). These results suggest that changes in gamma power do not explain the deficit in EDSS.

Other cognitive tasks are known to generate thalamocortical oscillations in the beta frequency range (12–30 Hz) (Fig. 4a,b). In the ASST, we recorded an increase in beta power during the trial compared to the ITI (Extended Data Fig. 6a). This beta activation was equivalent across both trial types and was not affected by the developmental manipulation (Extended Data Fig. 6b,c). In addition, we found no changes between trial types in thalamo-mPFC coherence (Extended Data Fig. 6c,d,f) or phase locking in the beta frequency range (Extended Data Fig. 6g,h).

Altogether, these data show that changes in oscillatory activity cannot explain the behavioral deficit in adolescent inhibited mice.

Adolescent thalamic activity regulates adult mPFC encoding. To determine whether thalamic inhibition alters encoding of information within the mPFC, we analyzed the firing rates of single units in the mPFC (Fig. 6a). Most mPFC units showed task-modulated activity, with cells showing either enhanced or decreased activity during the EDSS task trials compared to the ITI (Extended Data Fig. 7a–c). However, overall single-unit firing rates were not altered by either the developmental manipulation or the SSFO rescue (Fig. 6b). This was consistent during the ITI, over the course of the trial and in the predecision and postdecision periods when looking at either raw firing rates (Extended Data Fig. 7d–g) or firing rates that were normalized to ITI activity (Extended Data Fig. 8).

Furthermore, firing rates did not significantly vary between different trial types, such as correct trials and incorrect trials (Fig. 6c). Again, this was found throughout the different epochs of the trial (Extended Data Figs. 7 and 8). Thus, individual firing rates do not predict trial outcomes in control animals, and this metric was not affected by either developmental thalamic inhibition or acute thalamic activation. These findings were consistent, even when selecting only the task-modulated cells. Note that overall multiunit firing rates were also not changed in the MD thalamus during EDSS trials (Extended Data Fig. 9).

However, previous studies have highlighted the benefits of analyzing firing rates across populations of neurons to better elucidate task behaviors, contexts and outcomes (Fig. 6).

First, we analyzed the correlation between the firing of cells. We correlated peak cross-correlation values for each cell pair for each trial x to the outcome of trial x+1. This analysis showed that trial x+1 outcome is positively correlated with trial x peak cross-correlation (P = 0.025). This was true even when taking trial x outcome into account (that is, this was true across correct and incorrect trials), with no significant interaction of the effect of trial x cross-correlation and trial x outcome (P = 0.165). This analysis indicates that higher peak cross-correlation values for trial x are associated with improved performance in trial x+1.

Next, we explored the effects of thalamic inhibition on peak cross-correlations. Using a previous data set, we found that acute inhibition of thalamo-mPFC projections in adult mice decreases peak cross-correlation values for pairs of mPFC single units during the delay of a T-maze working memory task (Extended Data Fig. 10a).

We then analyzed cross-correlations for each cell pair during the EDSS trials. Adolescent thalamic inhibition reduced peak cross-correlations, and they were recovered following acute thalamic SSFO activation (Fig. 6d). This analysis supports the
hypothesis that higher peak cross-correlations lead to improved subsequent learning and behavioral outcomes, which are compromised following adolescent thalamic inhibition.

We also used a linear decoder to elucidate differences in population activity for trials that have different outcomes (Fig. 6e). Taking the firing rates for all cells in an experimental group across all trials, we trained a linear decoding algorithm using 50% of all trials for each cell to predict whether the behavioral outcome would yield a correct or incorrect trial. We then tested the decoder on the other 50% of trials to determine whether we could predict trial outcome based on cell firing rates. To determine chance performance, we used the same decoding algorithm using randomly shuffled trial outcomes repeated 1,000 times\(^2\). Using this decoder on the control group showed a resulting performance that was significantly better than chance at 74.71% accuracy (Fig. 6f). This finding was eliminated following adolescent thalamic inhibition, where the decoder was no better than chance at 43.25% accuracy. Crucially, acute thalamic enhancement rescued the decoder performance to 69.41% accuracy.

Of note, no subset of neurons contributed more to the decoder performance, with an even distribution across the populations in all three groups (Extended Data Fig. 10b,c). Similarly, the decoding performance discrepancies across groups are visible with randomly selected subgroups of neurons. The pattern can be seen with as few as five neurons (Extended Data Fig. 10d). Moreover, the control decoding performance was not observed when applied to trials in the IA portion of the ASST (Extended Data Fig. 10e), indicating the specificity of the role of the mPFC during the EDSS.
Together, these findings show that adolescent thalamic inhibition disrupts prefrontal encoding of EDSS task outcome in adulthood while decreasing correlated activity between prefrontal neurons. This disruption can be rescued by acute thalamic activation during adulthood.

**Discussion**

**An adolescent sensitive period for thalamo–mPFC development.**

Thalamic input activity has been shown to be important for sensory cortex maturation, including the visual cortex. More recent studies have also begun to explore how neuronal activity shapes the development of higher cognitive structures, such as the mPFC. Primarily, these studies have focused on changes to intrinsic components of mPFC circuitry, such as excitation and inhibition or layer II/III pyramidal neuron activity. Some studies have also highlighted similarities between mechanisms found in sensory-sensitive periods and mPFC adolescent development, including BDNF expression, NMDA receptor changes and the formation of peri-neuronal nets. Here, we explore whether afferent input from the thalamus shapes cortical maturation and whether inhibition of thalamic activity leads to long-lasting changes in mPFC function and behavior.

We found that thalamic inhibition during adolescence leads to persistent impairments in mPFC circuit function and cognitive behaviors in adulthood. Specifically, we observed impairments in two mPFC-dependent tasks assessing the acquisition of an NMS rule and attentional set shifting. These deficits were associated with a decrease in excitatory drive and anatomical projections to mPFC neurons. We determined that adolescence is a sensitive period because the impairments in behavior and excitatory drive were not observed following a comparable thalamic inhibition during adulthood. These results indicate that excitatory activity from the thalamus during adolescence is essential for thalamo–mPFC circuit development. This mirrors the findings in sensory-sensitive...
Fig. 6 | Adolescent thalamic inhibition leads to loss of mPFC cellular encoding of ASSt trial outcome in adult mice. a, Control light OFF mean firing rate during eDSS, normalized to ITI, before/after the decision point (dashed line). The color scale represents z-scored firing rate. b, No differences in firing rate occurred during the trial; control OFF, n = 8 animals, n = 75 cells and 3.650 ± 0.639 Hz; hM4D OFF, n = 12 animals, n = 55 cells and 3.487 ± 0.777 Hz; hM4D ON, n = 13 animals, n = 71 cells and 3.058 ± 0.516 Hz; one-way ANOVA, F_{2,194} = 0.2493 and P = 0.7796. Dots represent cells, and bars represent mean ± s.e.m. c, No differences in firing rate occurred during correct and incorrect trials; control OFF, firing rate correct 3.570 ± 0.647 Hz and incorrect 3.744 ± 0.630 Hz; two-sided paired t-test, t = 0.6546, d.f. = 71 and P = 0.5148; hM4D OFF: firing rate correct 3.607 ± 0.859 Hz and incorrect 3.676 ± 0.873 Hz; two-sided paired t-test, t = 0.3174, d.f. = 48 and P = 0.7523; hM4D ON: firing rate correct 3.058 ± 0.519 Hz and incorrect 3.023 ± 0.550 Hz; two-sided paired t-test, t = 0.1539, d.f. = 70 and P = 0.8781. Dots represent individual cells, and lines connect firing rate for correct and incorrect trials. d, Peak cross-correlations for cell pairs during correct (green) and incorrect (orange) trials show a decrease in hM4D OFF animals compared to control OFF and hM4D ON (the graph is truncated along the y-axis; the untruncated graph is in Extended Data Fig. 8g); control OFF, n = 6 animals, 73 cells and 507 cell pairs and 0.0177 ± 0.0430; hM4D OFF, n = 9 animals, 52 cells and 181 cell pairs and 0.0124 ± 0.0212; hM4D ON, n = 11 animals, 69 cells and 327 cell pairs and 0.0201 ± 0.0414; linear mixed effects model (peak cross-correlation ~ group + trial type + (1|cell pair) + (1|animal) + (1|cell 1) + (1|cell 2)), fixed effect of group: control OFF versus hM4D OFF *P = 0.041622 and hM4D OFF versus ON **P = 0.0090838. Bars with error represent mean ± s.e.m.; dots represent cell pairs. e, Schematic of linear decoder. Neither hypothetical cells’ firing rates can distinguish between correct and incorrect trials (dots along axes). When plotted together, a linear decoder (red line) can discriminate between outcomes in additional trials (light circles). f, Decoding trial outcome using eDSS firing rate. Decoder performance is significantly above chance for control OFF (blue), at chance for hM4D OFF (red) and rescued by thalamic activation (purple). Actual performance is in colored diamonds. Shuffled trial outcomes show chance performance, mean ± s.d. (black circles and lines) and individual shuffles (1,000; gray circles), two-sided z score to calculate P values; control OFF, n = 4 animals and 60 cells, actual 74.71%, shuffled 49.95 ± 3.75%, ****P = 3.9604 × 10^{-11}; hM4D OFF, n = 7 animals and 45 cells, actual 43.25%, shuffled 51.13 ± 7.49%, P = 0.2926; hM4D ON, n = 9 animals and 61 cells, actual 69.41%, shuffled 50.15 ± 3.08%, ****P = 3.9472 × 10^{-10}; *P < 0.05, **P < 0.01, ****P < 0.0001.
Adolescence is a key period of cortical maturation. We found that adolescence is a sensitive period for mPFC circuit development. Adolescence is known to be a period of vulnerability in the development of psychiatric disorders, such as schizophrenia, in humans\(^1,2,3,7\). Moreover, functional imaging studies have shown that thalamo–prefrontal hypoconnectivity, a finding in individuals with schizophrenia, is already present in young adolescents at clinical high risk for the disorder\(^8-11\). We chose to inhibit thalamic activity in mice during the P20–P50 window because it is known that the mPFC is maturing during this time\(^12-14\). In rodents, the volume of the mPFC peaks around P24, after which it decreases, reflecting a period of dendritic pruning in mPFC pyramidal neurons, which peaks around P30 (refs. \(^5,15-17\)). It has been postulated that this volumetric change and pruning could result, in part, from refinement of thalamocortical synaptic contacts during this period\(^18\). Furthermore, one classic hypothesis originally presented by Feinberg states that in schizophrenia, aberrant activity-dependent pruning during adolescence may lead to persistent changes in prefrontal circuit function\(^19\).

Although the literature describing the density of thalamo–mPFC projections during postnatal development is scarce, published data suggest that projections are already fully established at P10, followed by a decrease later on\(^20\). This suggests that adolescent inhibition mostly affects the stability of thalamo–mPFC projections and that projections that are not used during adolescence are pruned away. Moreover, the relative change in projection density between the control and developmentally manipulated animals is similar at P35 (39.4% reduction) and P90 (42.6% reduction), indicating that the difference in projection density between the groups comes primarily from thalamic inhibition early on between P20 and P35. Whether this reduction in thalamic input also leads to long-lasting changes in intracortical connectivity remains unclear. During the same time window, the mPFC undergoes changes in myelination and interneuron development, which together promote emergent changes in network activity and behavioral functionality\(^3,21,22\). Future studies will determine whether the decrease in excitatory events is fully explained by a decrease in thalamic input or whether there are changes within the mPFC at the level of intracortical synaptic connectivity. Our finding that the frequency and amplitude of inhibitory events is unaltered in the adult mPFC offers evidence against a strong involvement of interneurons in this process, although we did not determine whether cortical inhibition may have been altered during adolescence at the time of thalamic inhibition.

While we provide strong evidence that adolescence is a sensitive time window for thalamo–mPFC circuit maturation, the underlying mechanisms by which this occurs are unclear. The observation that activity is important for the development of thalamocortical projections suggests a Hebbian rule where projections that are not used are not stable. Recent studies also point to intracortical mechanisms in the maturation of cortical circuitry. DREADD-mediated inhibition of anterior cingulate-to-visional cortex projection neurons during adolescence has been shown to disrupt the maintenance of local connectivity within the anterior cingulate\(^23\). By analogy, if inhibition of thalamic inputs decreases activity of mPFC–thalamic projection neurons during adolescence, this may lead to a disruption in the maintenance of local excitation in the mPFC. A different mechanism has also been described within the visual cortex. DREADD-mediated inhibition of layer II/III neurons during the critical period of primary visual cortex development (P24–P29) led to excitatory synaptic scaling and increased intrinsic excitability, suggesting homeostatic plasticity as a mechanism affecting visual cortex maturation\(^24\). Future studies will be able to identify the exact plasticity mechanisms in mPFC circuitry that are induced by thalamic inhibition during adolescence.

Adolescent thalamic activity regulates adult mPFC circuitry. Thalamic projections to the mPFC are a crucial source of excitatory input to mPFC pyramidal cells. Following adolescent thalamic inhibition, we found reduced excitatory drive to mPFC pyramidal cells in adulthood. Due to the reduction in sEPSC frequency, but not amplitude, we hypothesized that this change was primarily driven by a reduction in presynaptic inputs and that decreased inputs from the thalamus may contribute to this change.

We confirmed this hypothesis through retrograde labeling. We believe this thalamo–mPFC projection reduction is due to a decrease in axonal arborization rather than thalamic cell numbers because DAPI staining in the thalamus was unchanged. This is consistent with the observation that the thalamus has already undergone a period of heightened apoptosis around P13, which is before the time window of our inhibition experiments\(^25,26\).

Adolescent thalamic inhibition had no effect on mPFC-projecting cells from another subcortical region, the BLA, indicating specificity to thalamocortical projections. This result is distinct from what has been observed after early developmental subcortical lesions, which showed a compensatory increase in BLA–mPFC projections following early postnatal (P7) ventral hippocampal lesions\(^27\). Because we used bilateral injections of retrograde virus to investigate the impact of developmental thalamic inhibition on cortical projections, we were unable to determine whether there were any changes to cortical–cortical contralateral projections. As already discussed above, future studies should examine whether intracortical connectivity is also affected.

Oscillatory activity cannot explain behavioral outcomes. Previous studies have shown the importance of task-induced gamma for predicting behavioral performance during EDSS and that this signal is persistently disrupted following adolescent inhibition of mPFC parvalbumin (PV) interneurons\(^28\). Here, we also found that mPFC gamma power was correlated with behavioral performance in control animals, with elevated gamma in correct trials compared to incorrect trials, but this pattern was not affected by adolescent thalamic inhibition. Consistent with unchanged gamma power after developmental thalamic inhibition, we did not find any deficits in cortical inhibition in adult mice (assessed by recording sIPSCs in cortical pyramidal cells). This is different from what had been observed following adolescent PV inhibition\(^29\) and suggests that the long-term consequences of adolescent thalamic inhibition may not involve cortical PV interneurons.

Beta oscillatory activity has also previously been identified in thalamo–prefrontal manipulations, often in the context of working memory behaviors\(^1,2,3\). While we did find task-induced beta oscillations, these were not correlated with behavioral outcome in controls and were not affected by adolescent thalamic inhibition.

Altogether, these data suggest that, despite reduced thalamic inputs to the mPFC, oscillatory measures of the thalamo–mPFC circuitry cannot explain the deficits observed during the EDSS behavior. Thus, while these oscillations may be necessary for the proper execution of this task, they are not the only mechanism at play.

The thalamus supports mPFC outcome encoding. To determine whether adolescent thalamic inhibition disrupts single-unit activity in the adult animal, we examined mPFC cell firing rates during EDSS trials. We found no changes in individual neuron firing rates across different trial types or throughout the trial. However, recent theories suggest that multiple neurons form ensembles that determine functional properties and outcomes in ways beyond single neuron firing\(^30,31\).
When we studied the cross-correlations between cell pairs, we found that cross-correlations were disrupted following adolescent thalamic inhibition, which is reminiscent of what we measured after acute thalamo–mPFC inhibition in the adult43. This disruption was rescued by acute thalamic activation. Together, these results point to a role of thalamic inputs in enhancing mPFC cellular communication. The decrease in cross-correlations following adolescent thalamic inhibition is found in both correct and incorrect trials, which likely reflects the fact that the animals are learning throughout the task, receiving feedback during both types of trials. Given the positive correlation between peak cross-correlation in trial x and trial x + 1 outcome regardless of trial x outcome, we further hypothesize that these cross-correlations allow the animals to incorporate feedback during both correct and incorrect trials. By contrast, following adolescent thalamic inhibition, the decreased cross-correlations across both trial types speaks to the animals’ inability to incorporate information during both correct and incorrect trials.

To further explore the effects on population encoding, we trained a linear decoding algorithm using a subset of trials to predict the EDSS trial outcome based on mPFC neuronal ensemble activity. Using this decoder, we were able to accurately predict trial outcome in control animals, but the decoding ability was down to chance levels following adolescent thalamic inhibition. Of note, this inability to decode does not necessarily imply that there is no information present in the activity. For example, there are several technical reasons why we may see a chance level decoder performance, including a high level of noise. Alternatively, hM4D animals with impaired thalamo–mPFC circuitry may be using a different circuit to perform the task, which could explain why activity of mPFC neurons no longer helps to predict trial outcome. Importantly, mPFC neurons regained the ability to encode task outcome after thalamic stimulation, suggesting that thalamic excitation rescues outcome encoding and task performance. Other thalamocortical circuits, namely in motor circuitry, have shown task-specific roles for both thalamic and cortical activity52. In addition, modifying activity of different mPFC cell types has also demonstrated task-specific roles for mPFC cellular subpopulations14. Meanwhile, thalamic input to the mPFC has been hypothesized to non-specifically amplify or sustain local mPFC connectivity and encoding15,16. This study supports the hypothesized role of the thalamus as a non-specific amplifier of mPFC cellular encoding during this cognitive flexibility task in two major ways. First, adolescent thalamic inhibition disrupted thalamo–mPFC projections in adulthood, which coincides with both reduced mPFC cellular cross-correlations and disrupted mPFC task outcome encoding. Second, non-specific thalamic activation, even in the context of fewer thalamic projections, during the EDSS was sufficient to restore cross-correlations and outcome encoding.

Prior studies have found that hyperactivation of mPFC neuronal populations can have detrimental effects, reflecting an inverted U-shaped pattern of mPFC neuronal activity and functional outcomes44,45. We found improved behavioral performance in the adolescent inhibited animals and no change in performance in the control animals during thalamic excitation. By facilitating activity of thalamic neurons that are engaged in the task, thalamic SSFO activation may not lead to the overstimulation of mPFC neurons. This is consistent with our finding that thalamic SSFO activation does not increase overall firing rates in the mPFC. Moreover, this finding further supports the theory of the thalamus as a facilitator of mPFC ensemble activity, as this manipulation may modulate activity of a subset of mPFC neurons without increasing overall mPFC activity.

The mPFC itself has been intensively studied in cognitive flexibility tasks, such as the ASST. Some studies have pointed to the postdecision period as a crucial point for the mPFC during the EDSS46. While we found mPFC encoding throughout the trial, the decoder performed better when using postdecision versus predecision period firing activity within a trial, indicating that the mPFC may indeed be particularly important in the period following the choice.

**The mPFC and the thalamus are interconnected in cognition.** Many of the analyses and interpretations in this study have focused on the impact of adolescent thalamic inhibition on adult mPFC functioning. However, separating mPFC function from thalamic function in the context of cognition is almost impossible, as the two regions are reciprocally connected. Thus, changing activity in one part of the circuit will change activity in the other part of the circuit. In agreement with this tenet, we found that cognitive deficits were associated with reduced thalamo–mPFC projections.

In addition, an analysis of intrinsic thalamic cellular properties revealed no changes in ex vivo slice sEPSC frequency and excitability, nor did we observe changes in the in vivo power in the epsilon band (>100 Hz, a metric for multunit activity)15. Together, these findings support a model in which the impact of transient thalamic inhibition during adolescence selectively disrupts thalamo–mPFC projections and prefrontal physiology, while the physiological properties of thalamic neurons are largely spared.

**Concurrent thalamic excitation as a therapeutic intervention.** Following thalamic inhibition during adolescence, we found persistent anatomical changes in thalamic projections to the mPFC. Nevertheless, we rescued the behavioral deficits by acutely exciting the thalamus in the adult mouse, even though this manipulation is unlikely to reverse the anatomical changes. It has previously been shown that exciting the thalamus during the delay of a prefrontal-dependent working memory task and a two-alternative forced choice task enhances performance in both tasks15,45. Our data suggest that the thalamus plays a broader function in amplifying mPFC activity that is not restricted to delay-containing cognitive processes. This result offers a major insight into potential therapeutic interventions in this circuit, as it indicates that even with persistent changes in circuit anatomy, a relatively non-specific thalamic excitation may still be able to improve behavior.

**Relevance for human disorders.** Human imaging studies have pointed to the importance of thalamo–prefrontal connectivity in cognitive functioning46–49. In individuals with schizophrenia, deficits in cognition have been related to hypoconnectivity between the thalamus and PFC, which is already seen in young adolescents before their diagnosis44,45. Indeed, given our findings, these early changes in thalamocortical functioning observed in adolescents at clinical high risk or with early onset schizophrenia may lead to long-lasting consequences on PFC function, which may increase the likelihood of severe cognitive deficits. Given the relevance of thalamo–prefrontal circuitry in psychiatric disorders like schizophrenia, this study offers key mechanistic insights into the etiology of, and potential therapies for, these disorders.

**Online content**
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41593-022-01072-y.

Received: 18 July 2021; Accepted: 5 April 2022; Published online: 19 May 2022

**References**
1. Takedian, A. E. & Hensch, T. K. Balancing plasticity/stability across brain development. Prog. Brain Res. 207, 3–34 (2013).
28. Guirado, R., Umemori, J., Sipila, P. & Castren, E. Evidence for competition in the primary auditory cortex (A1) in the rat. J. Neurosci. 27, 180–189 (2007).

26. Benoit, L. J. et al. Medial prefrontal lesions impair performance in an operant scoring task. J. Neurosci. 35, 10831–10842 (2015).

24. Schmitt, L. I. et al. Thalamic amplification of cortical connectivity sustains working memory maintenance. Schizophrenia Bull. 42, 181–186 (2016).

23. Rikhye, R. V., Gilra, A. & Halassa, M. M. Thalamic regulation of switching between cortical representations enables cognitive flexibility. Neuron 119, 68–72 (2021).

21. Van Eden, C. G. et al. Developmental regulation of parvalbumin-positive neuron subtypes in the prefrontal cortex. J. Neurosci. 37, 268–274 (1985).

20. Ferguson, B. R. & Gao, W. J. Development of thalamocortical connections between the mediodorsal thalamus and the prefrontal cortex and its implication in cognition. Front. Hum. Neurosci. 8, 1027 (2014).

19. Rios, O. & Villalobos, J. Postnatal development of the afferent projections from the dorsomedial thalamic nucleus to the frontal cortex in mice. Brain Res. Dev. Brain Res. 150, 47–50 (2004).

18. Uihlaas, P. J. & Singer, W. The development of neural synchrony and large-scale cortical networks during adolescence: relevance for the pathophysiology of schizophrenia and neurodevelopmental hypothesis. Schizophrenia Bull. 54, 135–165 (2017).

17. Wen, W. & Turrigiano, G. G. Developmental regulation of homeostatic plasticity in mouse primary visual cortex. J. Neurosci. 41, 9981–9995 (2021).

16. Guo, Z. V. et al. Maintenance of persistent activity in a frontal thalamocortical loop. Nature 545, 181–186 (2017).

15. Kamigaki, T. & Dan, Y. Delay activity of specific prefrontal interneuron subtypes modulates memory-guided behavior. Nat. Neurosci. 20, 1134–1139 (2008).

14. Rikhye, R. V., Gilra, A. & Halassa, M. M. Thalamic regulation of switching between cortical representations enables cognitive flexibility. Nature 21, 1753–1763 (2018).

13. Anticovic, A. et al. Association of thalamic dysconnectivity and conversion to psychosis in young and adult patients at elevated clinical risk. JAMA Psychiatry 72, 882–891 (2015).

12. Woodward, N. D. & Heckers, S. Mapping thalamocortical functional connectivity in chronic and early stages of psychotic disorders. Neurosci. Biobehav. Rev. 119, 68–72 (2021).

11. Weinberger, D. R. & Berman, K. F. Prefrontal function in schizophrenia: a review of the evidence from functional imaging studies. J. Psychiatr. Res. 149, 1495–1503 (1996).

10. Nakahara, E. et al. Adolescent frontal top–down neurons receive heightened local drive to establish adult attentional behavior in mice. Nat. Commun. 11, 3983 (2020).

9. Bicks, L. K. et al. Prefrontal parvalbumin interneurons require juvenile social experience to establish adult social behavior. Nat. Commun. 11, 1003 (2020).

8. Larsen, B. & Luna, B. Adolescence as a neurobiological critical period for the development of higher-order cognition. Neurosci. Biobehav. Rev. 94, 179–195 (2018).

7. Bitzenhofer, S. H., Pöpplau, J. A., Chini, M., Marquardt, A. & Hanganu-Opatz, I. L. A transient developmental increase in prefrontal activity alters network maturation and causes cognitive dysfunction in adult mice. Neuron 109, 1350–1364 (2021).

6. Benoit, L. J. et al. Medial prefrontal lesions impair performance in an operant scoring task. J. Neurosci. 35, 10831–10842 (2015).

5. Benoit, L. J. et al. Medial prefrontal lesions impair performance in an operant scoring task. J. Neurosci. 35, 10831–10842 (2015).

4. Benoit, L. J. et al. Medial prefrontal lesions impair performance in an operant scoring task. J. Neurosci. 35, 10831–10842 (2015).

3. de Villers-Sidani, E., Chang, E. F., Bao, S. & Merzenich, M. M. Critical period for thalamocortical functional development in chronic and early stages of psychotic disorders. Schizophrenia Bull. 31, 882–891 (2015).

2. Wiesel, T. N. & Hubel, D. H. Single-cell responses in striate cortex of kittens deprived of vision in one eye. J. Neurophysiol. 26, 1003–1017 (1963).

1. Wiesel, T. N. & Hubel, D. H. Single-cell responses in striate cortex of kittens deprived of vision in one eye. J. Neurophysiol. 26, 1003–1017 (1963).
Methods

Animal husbandry. All procedures were performed in accordance with guidelines approved by the Institutional Animal Care and Use Committees at Columbia University and the New York State Psychiatric Institute (protocol NYU-1499). Animals were housed under a 12-h light/12-h dark cycle in a temperature-controlled environment (22 °C, humidity of 30–70%) with food and water available ad libitum, unless otherwise noted. Offspring of heterozygous \( \text{Gfx2}^{+/\text{CreERT} } \) (Jackson Laboratories, 022135; back-crossed to C57BL/6) and C57BL6 females (Jackson Laboratories, 000664) were used for most experiments. At P10, tail samples were collected for genotyping (transnmy). At P13, Gfx2\(^{+/-}\) heterozygous mice were used for viral injections. Littermates were randomly assigned to each group, with random and equal distribution across males and females. Mice were housed together with dams and littermates. At P15 and P16, all offspring were given i.p. injections of tamoxifen (Sigma-Aldrich, T5648) dissolved in corn oil at 75 mg kg\(^{-1}\) to induce Cre recombination. Offspring were weaned at P28 and housed in same-sex littermates (five mice per cage).

For thalamic inhibition, mice were given i.p. injections of CNO dissolved in 0.9% saline at 1 mg kg\(^{-1}\) twice per day. All mice were given CNO regardless of viral vector or group. Throughout data collection and analysis, experimenters were blinded to the group of the animal. These injections took place every day from P20 to P50 for adolescent inhibition and from P90 to P120 for adult inhibition.

At P70, mice used for cell density studies were injected with virus, and mice used for in vivo optogenetic neurophysiology recordings during behavioral experiments were injected with virus and implanted with optodes. Implanted mice were subsequently housed in cages of two to three mice per cage.

All behavioral experiments in vivo recordings were done 40 d after the last CNO injection in adult mice. During behavioral training and testing, mice were food restricted and maintained at 85% of their initial weight.

For the dual virus approach, C57BL/6 males and females were bred, and all pups were used for the experiment. Surgeries were conducted at P13, and all mice were injected from P20 to P50 i.p. with JHU37160 (a CNO analog\(^{28}\); 0.9% saline, 0.01 mg kg\(^{-1}\) twice per day). We based sample sizes on previous experiments, and no statistical methods were used to calculate sample sizes\(^{6,26,28,59}\).

Surgical procedures. For viral injections at P13, mice were anesthetized with ketamine (4 mg ml\(^{-1}\)) and xylazine (0.6 mg ml\(^{-1}\)), and heads were fixed in a stereotactic apparatus (Kopf). Mice were injected bilaterally in the midline thalamic with AAV5-IhSyn-DIO-hM4D-mCherry (Addgene, 44362) or a control virus, either AAV5-IhSyn-DIO-EGFP (Addgene, 50457) or AAV5-IhSyn-DIO-mCherry (Addgene, 50459), at a volume of 0.25 μl (0.1 μl min\(^{-1}\)). For the dual virus approach surgeries at P13, mice were injected bilaterally in the midline thalamic with AAV5-IhSyn-DIO-hM4D-mCherry or the control AAV5-IhSyn-DIO-EGFP. Mice were also injected bilaterally in the mPFC with ngAAV-IhSyn-Cre-WPRE-hGH (Addgene, 105553) at a volume of 0.25 μl (0.1 μl min\(^{-1}\)).

The following were the P13 coordinates: thalamus, −1.0 anterior–posterior (AP), ±0.25 medial–lateral (ML) and −3.0 dorsal–ventral (DV; skull at bregma); mPFC, ±0.13 ML and −1.45 DV (skull at bregma). For surgeries at P70, mice were anesthetized with ketamine (10 mg ml\(^{-1}\)) and xylazine (1 mg ml\(^{-1}\)). Mice were injected bilaterally into the mPFC at +1.8 AP, ±0.35 ML and −2.5 DV (bregma) with retrograde AAV-CAG-GFP (Addgene, 37825) at a volume of 0.25 μl (0.1 μl min\(^{-1}\)).

In vivo optogenetic neurophysiology experiments, mice were anesthetized with isoflurane. All mice were injected bilaterally into the midline thalamus at 1.2 AP, ±0.35 ML and −3.2 DV (skull at bregma) with AAV5-CaMKII-hChR2(C128S/D156A)-EYFP (University of North Carolina Vector Core; 0.4 μl at 0.1 μl min\(^{-1}\)). During the same surgery, mice were implanted with an optrode consisting of a 36-channel narrow electronic interface board (Neuralynx), a single stereotrode bundle, and two flat-tipped, ferrule-coupled optical fibers (0.22 NA, 200 μm in diameter). Stereotrodes for recording spikes were made from 1.5-mm borosilicate glass pipettes on a P-97 puller (Sutter Instruments). Electrode impedance was typically 3–5 MΩ when filled with internal solution consisting of 130 mM potassium gluconate, 5 mM NaCl, 10 mM HEPES, 0.5 mM MgATP, and 0.3 mM Na-GTP (for thalamic recordings; pH 7.3, 280 mosm). Mice were habituated to the testing arena on day 1. On days 2–3, they were trained to dig in both bedding media (corn cob and paper pellet, both unscented) to obtain a food reward. Once mice dug reliably, testing began. For each trial, mice were placed at the opposite end from two identical stainless steel bowls containing different odor/medium combinations. For IA, mice needed to learn that the cinnamon scent, not the paprika scent, predicted a Honey Nut Cheerio reward, irrespective of the feeding medium. For the first five trials, mice could explore both bowls until they found the reward, but the trial was only scored as correct if the animal initially chose the correct bowl. From the sixth trial onward, once the mouse began digging in a bowl, the entrance to the other bowl was closed off. The criterion was reached when the mouse made eight of ten consecutive correct choices. If the mouse did not meet the criterion in 30 trials, the animal did not advance to the next stage (one animal from the adolescent manipulation hM4D group did not meet the IA criterion). If the mouse did reach the criterion, EDSS began. In EDSS, the animal needed to learn that the type of feeding medium (paper pellets, not corn cobs) predicted the Honey Nut Cheerio reward irrespective of odor. The criterion was reached with eight of ten consecutive correct choices.

For optogenetic experiments, mice completed the task twice 10 d apart. Animals were randomized to receive the light ON or OFF on run day 1 or run day 2 during EDSS. For run day 1, the rule in IA was the same as EDSS for run day 1, with paper rewarded. The rule in EDSS for run day 2 was odor (paprika) predicting the reward. For EDSS on the second run, mice that previously had the light ON for run day 1 had the light OFF and vice versa. There was no effect of run day on overall performance; therefore, light conditions were pooled across runs for analysis.

Optogenetic parameters. In optogenetic SSF experiments, for the light ON run, a 5-s blue light pulse (473 nm, 4 mW) was used for opsin activation before the first EDSS trial. Light was delivered via flat-tipped, 200-μm diameter, 0.22-NA optical fibers. To ensure continued opsins activation throughout EDSS, the 5-s pulse was repeated between trials every 30 min.

Slice electrophysiology. Whole-cell current and voltage clamp recordings were performed in layer II/III mPFC pyramidal cells and MD. Recordings were obtained with a Multiclamp 700B amplifier (Molecular Devices) and digitized using a Digidata 1440A acquisition system (Molecular Devices) with Clampex 10 (Molecular Devices) and analyzed with pClamp 10 (Molecular Devices). Following decapitation, 300-μm slices containing mPFC or MD were incubated in artificial cerebral spinal fluid containing 126 mM NaCl, 2.5 mM KCl, 2.0 mM MgCl\(_2\), 1.25 mM NaH\(_2\)PO\(_4\), 2.0 mM CaCl\(_2\), 26.2 mM NaHCO\(_3\), and 10.0 mM d-glucose bubbled with oxygen at 32 °C for 30 min before being returned to room temperature for at least 30 min before use. During recording, slices were perfused in artificial cerebral spinal fluid at a rate of 5 ml min\(^{-1}\). Electrodes were pulled from 1.5-mm borosilicate glass pipettes on a P-97 puller (Sutter Instruments). Electrode resistance was typically 3–5 MΩ when filled with internal solution consisting of 130 mM potassium gluconate, 5 mM NaCl, 10 mM HEPES, 0.5 mM MgATP, 2.5 mM Mg-ATP and 0.3 mM Na-GTP (for thalamic recordings; pH 7.3, 280 mosm) or 130 mM cesium gluconate, 10 mM HEPES, 2 mM MgCl\(_2\), 0.2 mM EGTA, 2.5 mM Mg-ATP, 0.3 mM Na-GTP and 5 mM lidocaine N-ethyl bromide (for pyramidal cell recordings; pH 7.3, 280 mosm).

MD recordings. Animals were killed at P35 or P105 after either receiving CNO or 2-AP5 and were perfused for 30 min with a 100 mM perfusion solution that was reilluminated (following a 0-s delay), signaling a second noseport entry. Following the second noseport entry, the choice phase began, and both levers were presented. If the animal pressed the opposite lever to the sample lever of that trial (non-match), the trial was recorded as ‘correct’, and a milk reward was given. If the animal pressed the same lever as the sample, the trial was recorded as ‘incorrect’, and the trial was not presented. This final step was followed by a 10-s ITI during which the house light was turned off. Acquisition was repeated every day with 120 trials per day. For the final 3 d, the total number of trials was increased to 160 trials. Throughout the experiment, mice were given unlimited time to complete the required trials. All mice achieved a criterion level of performance, which was defined as 3 consecutive days above 70% correct.
were induced at each recording site by passing current (50+10 mV; 60 s of the current recording before the decision point). Frequency ranges were defined as 40–90 Hz for gamma power, we fit linear mixed models with gamma power as outcome. The random effect was animal, and the fixed effect was either trial (ITI versus trial) or trial outcome type (correct versus incorrect). Power as a function of frequency was plotted by averaging the gamma power across the 6 s before the decision point. Mean power or coherence was calculated for those 6 s for the range of 40–90 Hz for gamma or 12–30 Hz for beta.

For analyzing firing rates, data were binned into 50-ms windows. Firing rates were smoothed for analysis (where indicated) by taking the average firing rate of the surrounding five bins (that is, 250 ms).

To represent z-scored firing rates, the mean and standard deviation was calculated for the firing rate for all EDSS ITI time bins. Smoothed firing rates for each time bin were calculated for the correct and incorrect trials in each condition. The EDSS function xcor was used to all pairs of cells within each animal using a maximum lag time of ±80 ms. The peak cross-correlation value for each cell pair was used in the analysis, with each cell pair having a peak cross-correlation during correct and incorrect trials. We then fit a linear mixed model with peak cross-correlation as outcome, fixed effects of group (control, hM4D, hM4D light ON), and trial outcome type (correct versus incorrect) and random effects of animal and cell. Because the analysis requires cell pairs, certain animals were removed from the analysis if they had only one isolated cell (control: 2 of 8; hM4D: 3 of 12; hM4D light ON: 2 of 13).

**Decoder.** The linear decoder was custom-written in Python. Smoothed firing rates for the 12 s around the decision (described above) and the trial outcome (that is, correct or incorrect) were used for each trial for the decoder. The analysis was done during ITI and EDSS of the ASST task. Certain animals were removed from the analysis if they had fewer than two neurons or fewer than two of each trial outcome (EDSS control: 4; hM4D: 4; hM4D light ON: 4; IA: control: 5). The decoder algorithm was based on linear classifiers trained on pseudosimultaneous (PS) population activity created by combining 50-ms binned neural patterns recorded from different animals performing the same behavioral task. The decoding algorithm was cross-validated and tested against a null model with shuffled trial condition labels.

**Cross-validation (CV).** We computed the decoding performance using a 20-fold CV scheme. For each CV fold, we randomly selected half of the trials of each condition and used them to build PS activity (see below), which was used to train a support vector machine with a linear kernel to classify PS patterns into one of the two conditions. Paired t-tests were used to compare the firing rates during correct and incorrect trials. We then fit a linear mixed model with peak cross-correlation as outcome, fixed effects of group (control, hM4D, hM4D light ON), and trial outcome type (correct versus incorrect) and random effects of animal and cell. Because the analysis requires cell pairs, certain animals were removed from the analysis if they had only one isolated cell (control: 2 of 8; hM4D: 3 of 12; hM4D light ON: 2 of 13).

**Pseudopopulation.** To build pseudopopulations, we randomly selected 50-ms binned neural patterns from training and testing trials of all animals and concatenated them to form a larger PS neural pattern. To obtain training and testing data sets used in the CV scheme, this procedure was repeated 10×N times per condition, where N is the total number of neurons.

n time bins decoding. To increase the signal-to-noise ratio of the decoder, we used a procedure where the decoder was trained to classify groups of n time bins sampled from the two conditions (n=1 corresponding to standard single-time bin decoding). In practice, this was done when building pseudopopulation activity by randomly sampling n different time bins for each individual animal to build a single PS time bin. Unless specified otherwise, we used n=5.

**Null model and P value.** All decoding performance values were tested against M replications of a null model by shuffling the condition labels of individual trials. After each shuffle of the labels, the exact same decoding procedure described above was repeated on the shuffled data. Unless specified otherwise, we used M=1,000. The P value associated with the decoding performance was computed by comparing the performance of the shuffled model to the performance of the data.

**Implementation.** The analysis was performed in Python3 using a linear classifier based on a support vector machine with custom-written Python scripts based on the scikit-learn SVC package.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
The source data that support the findings of this study are available on figshare at https://figshare.com/projects/Benoit_Kellendonk_NN-A76458A/135581 or from the corresponding author upon reasonable request.

Code availability
Med-PC V, MATLAB and Python code used for administering the behavior and analysis of the data that support the findings of this study is available on figshare at https://figshare.com/projects/Benoit_Kellendonk_NN-A76458A/135581 or from the corresponding author upon reasonable request.

References
58. Bonaventura, J. et al. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nat. Commun. 10, 4627 (2019).
59. Canetta, S. et al. Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Mol. Psychiatry 21, 956–968 (2016).
60. Vinck, M., van Wingerden, M., Womelsdorf, T., Fries, P. & Pennartz, C. M. The pairwise phase consistency: a bias-free measure of rhythmic neuronal synchronization. Neuroimage 51, 112–122 (2010).
61. Pedregosa, F. et al. Scikit-learn: machine learning in Python. J. Mach. Learn. Res. 12, 2825–2830 (2011).

Acknowledgements
We thank members of the C.K., S.C. and A.Z.H. labs for technical assistance and discussions. This work was supported by grants from the NIMH (K01MH107760 to S.C., R21 MH121334 and R21 MH117454 to C.K., F31 MH119691 to L.J.B., R01MH124998 to A.Z.H. and NSF Neuronex to L.P. and S.F.).

Author contributions
L.J.B., S.C. and C.K. designed the experiments. L.J.B. performed the experiments and analyzed the data. E.S.H. assisted in the performance and analysis of the experiments. A.Z.H. assisted in the design, performance, analysis and interpretation of experiments. L.P. and S.F. assisted in the analysis of experiments. L.J.B., S.C. and C.K. interpreted the results and wrote the paper.

Competing interests
The authors declare no competing interests.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41593-022-01072-y.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41593-022-01072-y.
Correspondence and requests for materials should be addressed to Christoph Kellendonk.

Peer review information Nature Neuroscience thanks the anonymous reviewers for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | A chemogenetic approach to reversibly and chronically inhibit thalamic cells during development or adulthood. (a) Experimental design and timeline. Mice were injected with virus at P13, and whole cell patch clamp recordings were made at P35, P50, or P105 in cells expressing hM4D-mCherry or control cells at baseline and in response to bath application of 10 μM. Animals expressing hM4D were given twice daily 1 mg/kg CNO i.p. injections for 15 days (P20-35 and P90-105) or 30 days (P20-50). Created with Biorender.com. (b) Example images illustrating hM4D-mCherry expression in the midline thalamus in adolescent and adult animals. Histology images were collected from each animal for each cohort, with at least 6 slices taken for each animal and at least 8 adolescent and 5 adult animals. (c) Superimposed traces of hM4D-mCherry viral spread (red shading) relative to mediodorsal and midline thalamic nuclei (dashed black lines) in coronal slices. Distance from bregma listed beside each coronal slice. (d) Quantification of CNO-induced hyperpolarization. Control cells at P35 and P105 were pooled because CNO did not show an effect at either age. CNO induced a significant hyperpolarization in P35, P50, and P105 cells expressing hM4D relative to control cells. Dots indicate individual cell responses and bars indicate mean ± SEM. Control: n = 15 cells, 5 animals; hM4D, P35 (CNO P20-35, 15 days): n = 8 cells, 3 animals; hM4D, P50 (CNO P20-50, 30 days): n = 5 cells, 2 animals; hM4D, P105 (CNO P90-105, 15 days): n = 5 cells, 3 animals; 1-way ANOVA, effect of treatment F(3, 29) = 4.573, p = 0.0097; Holm-Sidak post-hoc, Control vs. hM4D P35 *p = 0.0460, Control vs. hM4D P50 **p = 0.0095, Control vs. hM4D P105 *p = 0.0459. *p < 0.05.
Extended Data Fig. 2 | See next page for caption.
Extended Data Fig. 2 | (a) Adolescent-inhibited hM4D animals have a significantly worse performance during the first 8 days of the NMS task, particularly at day 4. Control: n = 17 animals; hM4D: n = 21 animals. 2-way rmANOVA, effect of time F(3.129,112.7) = 87.66, p < 0.0001, effect of group F(1,36) = 4.575, *p = 0.0358, effect of group x time F(7,252) = 1.546, p = 0.1523; Holm-Sidak post-hoc analysis day 4, *p = 0.0456. Learning curves depict mean performance ± SEM each day. b) In the NMS task, mobility and motivation were unaffected by adolescent (top) or adult (bottom) thalamic inhibition: mean trial length, adolescent: Control: n = 17 animals, 18.94 ± 1.61 s, hM4D: n = 21 animals, 19.03 ± 1.26 s; two-sided unpaired t-test: t = 0.04228, df = 36, p = 0.9665; adult: Control: n = 6 animals, 19.41 ± 4.19 s, hM4D: n = 10 animals, 19.05 ± 1.50 s; two-sided unpaired t-test: t = 0.09631, df = 14, p = 0.9665; (c) sample lever-choice lever press latency, adolescent: Control: 4.932 ± 0.199 s, hM4D: 5.372 ± 0.252 s; two-sided unpaired t-test: t = 1.321, df = 36, p = 0.1949; adult: Control: 5.304 ± 0.416 s, hM4D: 4.999 ± 0.102 s; two-sided unpaired t-test: t = 0.8949, df = 14, p = 0.3875. (d) Latency to collect reward, adolescent: Control: 0.5781 ± 0.0143 s, hM4D: 0.5801 ± 0.0125 s; two-sided unpaired t-test: t = 0.1086, df = 36, p = 0.9141; adult: Control: 0.6091 ± 0.0396 s, hM4D: 0.6137 ± 0.0233 s; two-sided unpaired t-test: t = 0.1064, df = 14, p = 0.9168, and (e) percentage of rewards retrieved, adolescent: Control: 99.78 ± 0.05%, hM4D: 99.71 ± 0.07%; two-sided unpaired t-test: t = 0.7668, df = 36, p = 0.4482; adult: Control: 99.36 ± 0.21%, hM4D: 99.62 ± 0.10 s; two-sided unpaired t-test: t = 1.399, df = 14, p = 0.2503. f) In the ASST, mobility and motivation were unaffected by adolescent (top) or adult (bottom) thalamic inhibition: median latency to dig during IA (adolescent: Control: n = 14 animals, 24.29 ± 5.84 s, hM4D: n = 16 animals, 32.47 ± 8.91 s; two-sided unpaired t-test: t = 0.7448, df = 28, p = 0.4626; adult: Control: n = 20 animals, 53.50 ± 9.41 s, hM4D: n = 17 animals, 45.44 ± 6.95 s; two-sided unpaired t-test: t = 0.6682, df = 35, p = 0.5084) or (g) SS (adolescent: Control: n = 14 animals, 34.57 ± 8.39 s, hM4D: n = 15 animals, 32.07 ± 4.32 s; two-sided unpaired t-test: t = 0.2708, df = 27, p = 0.7886; adult: Control: n = 20 animals, 90.20 ± 12.58 s, hM4D: n = 17 animals, 78.44 ± 13.70 s; two-sided unpaired t-test: t = 0.6323, df = 35, p = 0.5313). (h) EDSS error type breakdown, perseverative (P) and random (R), was unaffected. Adolescent inhibition (top) caused increased P and R errors (Control: n = 14 animals, hM4D: n = 15 animals; 2-way rmANOVA, effect of group F(1,27) = 4.215, *p = 0.0499). Adult inhibition (bottom) caused no change in error type (Control: n = 20 animals, hM4D: n = 17 animals; 2-way rmANOVA, effect of group F(1,35) = 1.369, p = 0.2499). Dots represent individual animals; lines represent mean ± SEM. *p < 0.05.
Extended Data Fig. 3 | Thalamo-mPFC projection activity during adolescence is required for adult cognitive flexibility. (a) Schematic for viral injections to target thalamo-mPFC projections. At P13, one virus was injected into the mPFC containing a retrogradely transported Cre driver, and another virus was injected into the thalamus containing floxed, Cre-dependent hM4D or the control GFP. Created with Biorender.com. (b) Example image illustrating hM4D-mCherry expression in the thalamo-mPFC projections. Histology images were collected from each animal, with at least 6 slices taken for each animal (n=14 animals). (c) Superimposed traces of hM4D-mCherry viral spread (red shading) relative to mediodorsal and midline thalamic nuclei (dashed black lines) in coronal slices. Distance from bregma listed beside each coronal slice. (d) Adolescent-inhibited hM4D animals are no different than controls in the IA portion of the ASST. Control: n=12 animals, 9.75 ± 0.70 trials; hM4D: n=14 animals, 10.00 ± 0.70 trials; two-sided unpaired t-test, t = 0.2507, df=24, p = 0.8042. Dots represent individual animals; lines represent mean ± SEM. (e) Adolescent-inhibited hM4D animals take significantly more trials in the EDSS to reach criterion than controls. Control: n=12 animals, 10.25 ± 0.37 trials; hM4D: n=14 animals, 13.00 ± 1.02 trials; two-sided unpaired t-test, t = 2.385, df=24, *p = 0.0254. Dots represent individual animals; lines represent mean ± SEM. *p < 0.05.
Extended Data Fig. 4 | Thalamic activity in adolescence is not required for thalamic cell activity in adulthood. (a) Adolescent experimental timeline and schematic. Whole-cell patch clamp recordings were made from thalamic cells from control and hM4D mice. These cells receive inputs from the mPFC and express the control or hM4D virus. Created with Biorender.com. (b) Representative traces showing spontaneous excitatory post-synaptic currents (sEPSCs). sEPSC (c) frequency and (d) amplitude are unchanged following adolescent thalamic inhibition relative to control mice. Control: n = 9 cells, 3 animals; hM4D: n = 8 cells, 2 animals; frequency: Control: 5.131 ± 1.234 Hz, hM4D: 3.710 ± 1.318 Hz; two-sided unpaired t-test, t = 0.7874, df = 15, p = 0.4433; amplitude: Control: 21.70 ± 0.98 pA, hM4D: 20.32 ± 0.89 pA; two-sided unpaired t-test, t = 1.023, df = 15, p = 0.3227. (e) Representative traces showing events in current clamp recordings. (f) Rheobase is unchanged following adolescent thalamic inhibition, as is (g) firing frequency in response to input currents. Control: n = 8 cells, 3 animals; hM4D: n = 8 cells, 2 animals; rheobase: Control: 21.75 ± 4.41 pA, hM4D: 21.25 ± 8.33 pA; two-sided unpaired t-test, t = 0.000, df = 14, p > 0.9999; input current vs. firing frequency: 2-way rmANOVA, effect of input current F(2.484, 34.59) = 48.33, p < 0.0001, effect of group F(1, 14) = 0.08940, p = 0.7693, effect of group x input current F(14, 195) = 0.4870, p = 0.9383. Curves depict mean firing frequency ± SEM for each input current. For all other plots, dots represent individual animals; lines represent mean ± SEM.
Extended Data Fig. 5 | Density of thalamic projections to the mPFC is already decreased at P35. (a) After twice daily CNO injections from P20-35, stereological estimates of thalamo-mPFC projections at P35 showed a significant decrease in density in adolescent-inhibited hM4D animals compared to controls (Control: n = 9 animals, 762.3 ± 110.9 cells/mm², hM4D: n = 10 animals, 462.1 ± 87.21 cells/mm²; two-sided unpaired t-test, t = 2.149, df=17, *p = 0.0463). (b) Meanwhile, there were no differences in overall thalamic area (Control: n = 9 animals, 6.262 ± 0.176 mm², hM4D: n = 10 animals, 6.231 ± 0.072 mm²; two-sided unpaired t-test, t = 0.1712, df=17, p = 0.8661). (c) Moreover, there is a higher density of thalamo-mPFC projections at P35 than at P90 (P35: Control: n = 9 animals, hM4D: n = 10 animals; P90: Control: n = 6 animals, hM4D: n = 7 animals; 2-way rmANOVA, effect of age F(1,28)=7.731, **p = 0.0096, effect of group F(1,28)=7.205, *p = 0.0121, effect of age x group F(1,28)=0.3405, p = 0.5642). Dots represent individual animals; lines represent mean ± SEM. *p < 0.05, **p < 0.01.
Extended Data Fig. 6 | See next page for caption.
Extended Data Fig. 6 | Mean thalamic beta (12-30 Hz) power is specifically enhanced during the EDSS trials compared to the ITI for (a) control (n = 10 animals, ITI: 0.1822 ± 0.0042; Trial: 0.2044 ± 0.0036; linear mixed effects model (power-trial + (1|animal)): fixed effect (Trial), ****p = 3.2642e-16) and (b) hM4D (n = 15 animals, ITI: 0.1866 ± 0.0018; Trial: 0.2124 ± 0.0022; linear mixed effects model (power-trial + (1|animal)): fixed effect (Trial), ****p = 2.0872e-41) animals. (c) As in (a) except for mean beta (12-30 Hz) mPFC-thalamic coherence (n = 10 animals, ITI: 0.3890 ± 0.0090; Trial: 0.4146 ± 0.0080; linear mixed effects model (coherence-trial + (1|animal)): fixed effect (Trial), ****p = 2.0137e-07). (d) As in (b) except for mean beta mPFC-thalamic coherence (n = 15 animals, ITI: 0.3968 ± 0.0044; Trial: 0.4331 ± 0.0044; linear mixed effects model (coherence-trial + (1|animal)): fixed effect (Trial), ****p = 6.7099e-19). (e) Mean thalamic beta power (n = 10 animals, 88 correct trials, 23 incorrect trials, Correct: 0.2052 ± 0.0041; Incorrect: 0.2011 ± 0.0075; linear mixed effects model (power-trial type + (1|animal)): fixed effect (Trial Type), p = 0.18827) and (f) beta mPFC-thalamic coherence (n = 10 animals, Correct: 0.4188 ± 0.0092; Incorrect: 0.3984 ± 0.0152; linear mixed effects model (coherence-trial type + (1|animal)): fixed effect (Trial Type), p = 0.72808) are unchanged across trial types in controls. Dots represent individual trials for each animal (colors of the dots). Lines and error represent mean ± SEM. g) Pairwise phase consistency (PPC) values show no differences between phase-locking of mPFC cell firing and thalamic beta oscillatory activity in control (n = 6 animals, 27 cells, Correct PPC: 0.01575 ± 0.00420; Incorrect: 0.01904 ± 0.00642; two-sided paired t-test: t = 0.4114, df=26, p = 0.6841) or (h) hM4D (n = 7 animals, 22 cells, Correct: 0.01623 ± 0.00441; Incorrect: 0.01205 ± 0.00561; two-sided paired t-test: t = 0.7443, df=21, p = 0.4649) animals. Dots represent individual cells, with lines connecting each cell’s correct and incorrect PPC value. ****p < 0.0001.
Extended Data Fig. 7 | See next page for caption.
Extended Data Fig. 7 | Breakdown of cells by behavior during the trial compared to the inter-trial interval (ITI), with cells that have a significantly increased firing rate during the trial (increasers), decreased firing rate (decreasers), or unchanged firing rate compared to the ITI (non-changers). This shows a majority of cells modulated during EDSS trials, with (a) 80% modulated in control animals, (b) 81.82% modulated in adolescent-inhibited hM4D animals, and (c) 71.83% modulated in hM4D animals during EDSS thalamic activation. d) Raw firing rates show no differences between groups across different epochs of the EDSS: during the ITI (Control Light OFF: n = 8 animals, 75 cells, 3.503 ± 0.561Hz; hM4D Light OFF: n = 12 animals, 55 cells, 2.619 ± 0.645 Hz; hM4D Light ON: n = 13 animals, 71 cells, 2.877 ± 0.570 Hz; 1-way ANOVA, F(2,194)=0.5002, p = 0.6072, dots represent individual cells; lines represent mean ± SEM), (e) over the course of the trial (overlapping 2 s bins, with x-axis labels depicting the middle of each bin; dots represent mean FR for each bin, error bars represent SEM); Control Light OFF: n = 8 animals, 75 cells; hM4D Light OFF: n = 12 animals, 55 cells; hM4D Light ON: n = 13 animals, 71 cells; 2-way rmANOVA, effect of group, F(2,194)=0.2743, p = 0.7604), during the (f) pre-decision (all trials: Control Light OFF: n = 8 animals, 75 cells, 3.717 ± 0.634 Hz; hM4D Light OFF: n = 12 animals, 55 cells, 3.482 ± 0.765 Hz; hM4D Light ON: n = 13 animals, 71 cells, 3.097 ± 0.533 Hz; 1-way ANOVA, F(2,194)=0.2492, p = 0.7797; correct vs. incorrect: 2-way rmANOVA, Holm-Sidak post-hoc, Control Light OFF: p = 0.9962, hM4D Light OFF: p > 0.9999, hM4D Light ON: p = 0.9707) and (g) post-decision (all trials: Control Light OFF: n = 8 animals, 75 cells, 3.585 ± 0.650 Hz; hM4D Light OFF: n = 12 animals, 55 cells, 3.493 ± 0.795 Hz; hM4D Light ON: n = 13 animals, 71 cells, 3.014 ± 0.500 Hz; 1-way ANOVA, F(2,194)=0.2693, p = 0.7642; correct vs. incorrect: 2-way rmANOVA, Holm-Sidak post-hoc, Control Light OFF: p = 0.6988, hM4D Light OFF: p = 0.9761, hM4D Light ON: p = 0.9475) periods, both across trial types (left; dots represent individual cells; lines represent mean ± SEM) and between correct and incorrect trials (right; dots represent individual cells, lines connecting FR for correct and incorrect trials).
Extended Data Fig. 8 | See next page for caption.
Extended Data Fig. 8 | Firing rates normalized to the ITI show no differences between groups across different EDSS epochs (for a-f: Control OFF: \( n = 8 \) animals, 75 cells; hM4D OFF: \( n = 12 \) animals, 55 cells; hM4D ON: \( n = 13 \) animals, 71 cells): (a) during the trial (Control OFF: 7.250 ± 3.907; hM4D OFF: 6.442 ± 2.351; hM4D ON: 2.353 ± 1.556; 1-way ANOVA, \( F(2, 194) = 1.346, p = 0.2628 \); dots represent individual cells; lines represent mean ± SEM), (b) between trial types (2-way rmANOVA, Holm-Sidak post-hoc, Control OFF: \( p = 0.2067 \), hM4D OFF: \( p = 0.9981 \), hM4D ON: \( p = 0.9848 \); dots represent individual cells, lines connecting FR for correct and incorrect trials), (c) over the course of the trial (overlapping 2 s bins, with x-axis labels depicting the middle of each bin; dots represent mean FR, error bars represent SEM; 2-way rmANOVA, effect of group, \( F(2, 194) = 0.9097, p = 0.4044 \)), (d) during the ITI (Control OFF: −0.7287 ± 0.2749; hM4D OFF: −1.508 ± 0.2542; hM4D ON: −0.7053 ± 0.2727; 1-way ANOVA, \( F(2, 194) = 0.5465, p = 0.5798 \); dots represent individual cells; lines represent mean ± SEM), (e) pre-decision (all trials: Control OFF: 7.898 ± 4.166; hM4D OFF: 6.356 ± 2.273; hM4D ON: 2.716 ± 1.722; 1-way ANOVA, \( F(2, 194) = 1.241, p = 0.2914 \); correct vs. incorrect: 2-way rmANOVA, Holm-Sidak post-hoc, Control OFF: \( p = 0.5151 \), hM4D OFF: \( p = 0.9999 \), hM4D ON: \( p = 0.9947 \)), (f) post-decision (all trials: Control OFF: 6.608 ± 3.720; hM4D OFF: 6.521 ± 2.443; hM4D ON: 1.993 ± 1.440; 1-way ANOVA, \( F(2, 194) = 1.441, p = 0.2391 \); correct vs. incorrect: 2-way rmANOVA, Holm-Sidak post-hoc, Control OFF: \( p = 0.2171 \), hM4D OFF: \( p = 0.9994 \), hM4D ON: \( p = 0.9347 \)), across trial types (left; dots represent individual cells; lines represent mean ± SEM) and between trial types (right; dots represent individual cells, lines connecting FR for correct and incorrect trials). (g) Un-truncated plot from Fig. 6d. Control OFF: \( n = 6 \) animals, 73 cells, 507 cellpairs, 0.0177 ± 0.0430; hM4D OFF: \( n = 9 \) animals, 52 cells, 181 cellpairs, 0.0124 ± 0.0212; hM4D ON: \( n = 11 \) animals, 69 cells, 327 cellpairs, 0.0201 ± 0.0414; linear mixed effects model (peak cross-correlation-group-outcome + (1|cellpair) + (1|animal) + (1|cell1) + (1|cell2)), fixed effect of group: Control OFF vs. hM4D OFF: \( *p = 0.041622 \); hM4D OFF vs. hM4D ON: \( **p = 0.0090838 \). Bars with error represent mean ± SEM. Individual dots represent cell pair correlations for each trial type. (h) FRs of cells with peak cross-correlation above 0.08 show no FR pattern. Dots represent cells, lines connecting each cell’s FR for correct and incorrect trials. Control OFF: \( n = 6 \) animals, 33 cells; hM4D OFF: \( n = 3 \) animals, 6 cells; hM4D ON: \( n = 5 \) animals, 26 cells.
Extended Data Fig. 9 | Mean thalamic epsilon firing rates during EDSS trials for each animal show no significant differences in thalamic activity for control or adolescent-inhibited hM4D animals. Control: n = 10 animals, 8.606 ± 2.114 Hz; hM4D: n = 15 animals, 5.726 ± 1.499 Hz; two-sided unpaired t-test, t = 1.144, df=23, p = 0.2643. Dots represent individual animals; lines represent mean ± SEM.
Extended Data Fig. 10 | See next page for caption.
Extended Data Fig. 10 | (a) Peak cross-correlation values for pairs of mPFC single units during the delay of a working memory T-maze task for correct (green) and incorrect (orange) trials, as described in Bolkan et al 201721. Acute thalamo-mPFC inhibition (Light ON) during the delay shows decreased cross-correlations compared with baseline (Light OFF). n = 9 animals, 891 cells, 5254 cell pairs; Light OFF: 0.0048 ± 0.0002; Light ON: 0.0043 ± 0.0002; linear mixed effects model (peak cross-correlation~group+trial type+(1|cellpair)+(1|animal)+(1|cell1)+(1|cell2)), fixed effect of group: Light OFF vs. ON: ****p = 3.587e-17. Bars with error represent mean ± SEM. Individual dots represent cell pairs. This graph has been truncated along the y-axis. (b) Histogram of control (blue), hM4D (red), and hM4D Light ON (gold) cell decoding weights show the distribution of contributions across cells is unchanged across groups. (c) Firing rates of cells with a significantly elevated decoding weight relative to shuffled data. Very few cells (<10% for each group) contribute significantly more than when shuffled, and these cells do not have different FRs across correct and incorrect trials. Dots represent cell FRs for each trial type, lines connecting each cell’s correct and incorrect trials. Control: n = 3 animals, 7 cells; hM4D: n = 1 animal, 1 cell; hM4D Light ON: n = 2 animals, 5 cells. (d) Decoder performance was calculated using random subgroups of neurons, repeated 25 times for each multiple of 5 neurons. Significant separation between hM4D and both Control and hM4D Light ON groups is seen with 5 neurons. Dashed line represents chance performance (50%). Dots represent mean performance for the repetitions, error bars represent standard deviation. Control Light OFF: n = 4 animals, 60 cells; hM4D Light OFF: n = 7 animals, 45 cells; hM4D Light ON: n = 9 animals, 61 cells; 2-way rmANOVA Holm-Sidak post-hoc analysis, with 5 neurons: Control vs. hM4D: p < 0.0001, Control vs. hM4D Light ON: p = 0.1557, hM4D vs. hM4D Light ON: p < 0.0001. (e) Decoding performance (blue diamond) is no better than chance for control animals during IA. Shuffled trial outcomes show chance decoder performance, mean ± standard deviation (black circles and error bars) and individual shuffles (grey circles). n = 3 animals, 47 cells, 1000 shuffles; actual: 50.35%, shuffled: 50.13 ± 3.14%, p = 0.9438.
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- n/a Confirmed
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
- Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

In vitro recordings were obtained with a Multiclamp 700B amplifier (Molecular Devices) and digitized using a Digidata 1440A acquisition system (Molecular Devices) with Clampex 10 (Molecular Devices), detected using MiniAnalysis (Synaptosoft) version 6, and analyzed with pClamp 10 (Molecular Devices). StereoInvestigator software (MBF Biosciences, Williston, VT, USA) was used for stereology. In vivo recordings were amplified, band-pass filtered (1-1000 Hz LFPs; 600-6000 Hz spikes) and digitized using a Digital Lynx system (Neuralynx Cheetah 6.4.2).

Data analysis

Statistical analysis and graph preparation for all data was done with Prism 9 software (Graphpad Software, San Diego, CA, USA) or custom scripts in MATLAB (2021a, Mathworks, Natick, MA, USA) and Python.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The data that support the findings of this study are available on figshare or from the corresponding author upon reasonable request.
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | For all experiments, sample size was determined by a power analysis following initial pilot study data analysis. |
|------------|---------------------------------------------------|
| Data exclusions | Exclusion criteria were pre-established to be able to do within animal analyses. For cross-correlations, certain animals were removed from the analysis if they had only one isolated cell (Control: 2 eliminated animals; hM4D: 3; hM4D Light ON: 2) because analysis requires cell pairs. For the linear decoder, certain animals were removed from the analysis if they had fewer than 2 neurons or fewer than 2 of each trial outcome (EDSS: Control: 4 eliminated animals; hM4D: 5; hM4D Light ON: 4; IA: Control: 5). |
| Replication | The behavioral findings were replicated in several experimental groups (1) behavior group from Fig. 1 and optogenetic group from Fig. 4 repeated the ASST findings; 2) behavior group 1 for the NMS was replicated in 3 separate cohorts; 3) in vitro electrophysiology group from Fig. 2 was replicated in 2 separate cohorts; 4) in vivo electrophysiology findings were replicated in an original pilot experiment (a smaller group conducted without optogenetics)). All attempts at replication were successful. |
| Randomization | Allocation was random. Each litter was divided across control and hM4D groups. Males and females were evenly distributed across groups. |
| Blinding | Investigators were blinded to the group of each animal during data collection and analysis. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

**Materials & experimental systems**

| n/a | Involved in the study |
|-----|-----------------------|
| ✗   | Antibodies            |
| ✗   | Eukaryotic cell lines |
| ✗   | Palaeontology and archaeology |
| ✗   | Animals and other organisms |
| ✗   | Human research participants |
| ✗   | Clinical data |
| ✗   | Dual use research of concern |

**Methods**

| n/a | Involved in the study |
|-----|-----------------------|
| ✗   | ChIP-seq              |
| ✗   | Flow cytometry        |
| ✗   | MRI-based neuroimaging |

**Antibodies**

The following primary antibodies were used: mCherry (rabbit anti-dsred; Takara Bio, Mountainview, CA, USA; 632496, 1:250) or green fluorescent protein (chicken anti-GFP; Abcam, Cambridge, UK, ab13970, 1:1000). Primary antibody incubation was 48 hours at 4°C. Alexa Fluor-conjugated secondary antibodies (donkey anti-rabbit Alexa Fluor-546 and goat anti-chicken Alexa Fluor-488, Invitrogen, 1:1000) were used for secondary detection.

**Validation**

rabbit anti-dsred Takara: from manufacturer: The quality and performance of this lot of Living Colors DsRed Polyclonal Antibody was tested by Western blot analysis. Lysate (10 μl; equivalent to 35,000 cells) from untransfected HEK 293 cells and lysates (10 μl; equivalent to 35,000 cells) from HEK 293 cells stably expressing DsRed-Express or AgGFP1 were resolved on a 12% SDS polyacrylamide gel and then transferred to a nitrocellulose membrane. The membrane was probed with the Living Colors DsRed Polyclonal Antibody (diluted 1:1,000), followed by secondary goat anti-rabbit antibody conjugated to horseradish peroxidase. The HRP signal was detected by chemiluminescence. A specific band of approximately 30–38 kDa was observed in the lane loaded with lysate from cells expressing DsRed-Express. No band in this molecular weight range was detected for the lysates of the untransfected HEK 293 cells or the cells expressing AgGFP1.

It is certified that this product meets the above specifications, as reviewed and approved by the Quality Department.

chicken anti-GFP Abcam: from manufacturer: The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Success from the first experiment -- confirmed specificity through extensive validation. Our GFP antibody does cross-react with the many fluorescent proteins that are derived from the jellyfish Aequorea victoria. These are all
proteins that differ from the original GFP by just a few point mutations (EGFP, YFP, mVenus, CFP, BFP). Positive control: ICC: GFP-transfected NIH/3T3 (Mouse embryo fibroblast cell line).

Invitrogen: from manufacturer: Antibodies are some of the most critical research reagents used in the lab. Poor specificity or application performance can significantly frustrate the ability to obtain good results, which can cause critical delays. Underperforming antibodies result in a lack of reproducibility, wasting time and money. In other words, researchers need antibodies that bind to the right target and work in their applications every time. To help ensure superior antibody results, we've expanded our specificity testing methodology using a 2-part approach for advanced verification: target specificity verification, and functional application validation.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

| Laboratory animals | Mouse. Heterozygous GBX2-CreERT (Jackson Labs, Stock #022135) males, back-crossed for at least 5 generations, were bred with C57/Bl6 females (Jackson Labs, Stock #000664) to produce offspring that were used in all experiments. Male and female offspring were used for the experiments, which spanned from breeding up to postnatal day 200. |
| Wild animals | The study did not involve wild animals. |
| Field-collected samples | The study did not involve samples collected from the field. |
| Ethics oversight | All animal procedures were done in accordance with guidelines derived from and approved by the Institutional Animal Care and Use Committees at Columbia University and the New York State Psychiatric Institute. |

Note that full information on the approval of the study protocol must also be provided in the manuscript.